Cognitive & Neuro

Cerebrolysin

Also known as FPF-1070 · Porcine brain peptide preparation

Emerging researchIntravenous infusionIntramuscular injectionApproved in many European and Asian countries for stroke, TBI, and dementia; not FDA-approved in the United States; Cochrane reviews rate the overall evidence quality as low to very low

Cerebrolysin is a standardized mixture of low-molecular-weight neuropeptides and free amino acids purified from porcine brain tissue. Its low-molecular-weight fragments are proposed to cross the blood-brain barrier and mimic endogenous neurotrophic factors such as BDNF, NGF, and GDNF, supporting neuronal survival, synaptic plasticity, and inhibition of apoptosis. It has been studied across Alzheimer's disease, vascular dementia, stroke, and traumatic brain injury, with mixed and often low-quality evidence.

Studied / used for

studied for Alzheimer's disease and vascular dementia
studied for ischemic stroke and traumatic brain injury recovery
studied for neuroprotection after brain injury

Commonly reported side effects

injection-site reactions
dizziness or headache
agitation or feeling hot
nausea; some pooled analyses reported an increase in non-fatal serious adverse events in acute ischemic stroke

Emerging research. Active research; human evidence still developing. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds